The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 20, 2022

Filed:

Sep. 24, 2020
Applicant:

The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US);

Inventors:

Everett Hurteau Meyer, Belmont, CA (US);

Robert S. Negrin, Stanford, CA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C12N 5/0789 (2010.01); A61K 35/17 (2015.01); A61P 37/06 (2006.01); A61K 31/445 (2006.01); A61K 39/00 (2006.01); C12N 5/0783 (2010.01); A61P 35/02 (2006.01); A61K 31/436 (2006.01); A61K 35/28 (2015.01); A61K 35/12 (2015.01);
U.S. Cl.
CPC ...
C12N 5/0647 (2013.01); A61K 31/436 (2013.01); A61K 31/445 (2013.01); A61K 35/17 (2013.01); A61K 35/28 (2013.01); A61K 39/001 (2013.01); A61P 35/02 (2018.01); A61P 37/06 (2018.01); C12N 5/0637 (2013.01); A61K 2035/122 (2013.01); C12N 2506/11 (2013.01);
Abstract

The disclosure provides methods for improved hematopoietic stem cell transplantations, including methods to enhance protection from graft versus host disease while maintaining effective immune responses such as graft versus tumor immune responses. The disclosure provides methods for administering, for example, hematopoietic stem and progenitor cells, regulatory T cells, and conventional T cells, wherein the conventional T cells are administered after the hematopoietic stem and progenitor cells and regulatory T cells. The disclosure also provides methods for administering, for example, hematopoietic stem and progenitor cells, regulatory T cells, and conventional T cells, wherein the regulatory T cells have not been cryopreserved prior to administration.


Find Patent Forward Citations

Loading…